Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID6235]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 March 2026
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) (TA965)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2024
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 6 August 2026
Mepolizumab for treating chronic obstructive pulmonary disease with eosinophil-associated exacerbations TSID12019Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Roflumilast for treating chronic obstructive pulmonary disease (TA461)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 July 2017
Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy [ID6711]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC